PMID- 32149463
OWN - NLM
STAT- MEDLINE
DCOM- 20210429
LR  - 20210429
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 24
IP  - 8
DP  - 2020 Apr
TI  - Exosome derived from CD137-modified endothelial cells regulates the Th17 
      responses in atherosclerosis.
PG  - 4659-4667
LID - 10.1111/jcmm.15130 [doi]
AB  - The role of exosomes derived from endothelial cells (ECs) in the progression of 
      atherosclerosis (AS) and inflammation remains largely unexplored. We aimed to 
      investigate whether exosome derived from CD137-modified ECs (CD137-Exo) played a 
      major role in AS and to elucidate the potential mechanism underlying the 
      inflammatory effect. Exosomes derived from mouse brain microvascular ECs treated 
      with agonist anti-CD137 antibody were used to explore the effect of CD137 
      signalling in AS and inflammation in vitro and vivo. CD137-Exo efficiently 
      induced the progression of AS in ApoE(-/-) mice. CD137-Exo increased the 
      proportion of Th17 cells both in vitro and vivo. The IL-6 contained in CD137-Exo 
      which is regulated by Akt and NF-capital KA, CyrillicB pathway was verified to activate Th17 cell 
      differentiation. IL-17 increased apoptosis, inhibited cell viability and improved 
      lactate dehydrogenase (LDH) release in ECs subjected to inflammation induced by 
      lipopolysaccharide (LPS). The expression of soluble intercellular adhesion 
      molecule1 (sICAM-1), monocyte chemoattractant protein-1 (MCP-1) and E-selectin in 
      the supernatants of ECs after IL-17 treatment was dramatically increased. 
      CD137-Exo promoted the progression of AS and Th17 cell differentiation via NF-capital KA, CyrillicB 
      pathway mediated IL-6 expression. This finding provided a potential method to 
      prevent local and peripheral inflammation in AS.
CI  - (c) 2020 The Authors. Journal of Cellular and Molecular Medicine published by 
      Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
FAU - Xu, Liangjie
AU  - Xu L
AD  - Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, 
      China.
FAU - Geng, Tianxin
AU  - Geng T
AD  - Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, 
      China.
FAU - Zang, Guangyao
AU  - Zang G
AD  - Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, 
      China.
FAU - Bo, Li
AU  - Bo L
AD  - Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, 
      China.
FAU - Liang, Yi
AU  - Liang Y
AD  - Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, 
      China.
FAU - Zhou, Hong
AU  - Zhou H
AD  - School of Medicine, Jiangsu University, Zhenjiang, China.
FAU - Yan, Jinchuan
AU  - Yan J
AUID- ORCID: 0000-0001-6050-8007
AD  - Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200309
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (Apolipoproteins E)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (Tnfrsf9 protein, mouse)
RN  - 0 (Tumor Necrosis Factor Receptor Superfamily, Member 9)
SB  - IM
MH  - Animals
MH  - Apolipoproteins E/*genetics
MH  - Atherosclerosis/chemically induced/*genetics/pathology
MH  - Brain/metabolism/pathology
MH  - Cell Differentiation/genetics
MH  - Endothelial Cells/metabolism/pathology
MH  - Exosomes/*genetics
MH  - Gene Expression Regulation/genetics
MH  - Humans
MH  - Inflammation/chemically induced/*genetics/pathology
MH  - Lipopolysaccharides/toxicity
MH  - Mice
MH  - Mice, Knockout
MH  - NF-kappa B/genetics
MH  - Signal Transduction/genetics
MH  - Th17 Cells/metabolism/pathology
MH  - Tumor Necrosis Factor Receptor Superfamily, Member 9/*genetics
PMC - PMC7176883
OTO - NOTNLM
OT  - atherosclerosis
OT  - endothelial cells; Th17 cells
OT  - exosomes
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/03/10 06:00
MHDA- 2021/04/30 06:00
PMCR- 2020/04/01
CRDT- 2020/03/10 06:00
PHST- 2019/10/27 00:00 [received]
PHST- 2020/01/13 00:00 [revised]
PHST- 2020/01/23 00:00 [accepted]
PHST- 2020/03/10 06:00 [pubmed]
PHST- 2021/04/30 06:00 [medline]
PHST- 2020/03/10 06:00 [entrez]
PHST- 2020/04/01 00:00 [pmc-release]
AID - JCMM15130 [pii]
AID - 10.1111/jcmm.15130 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2020 Apr;24(8):4659-4667. doi: 10.1111/jcmm.15130. Epub 2020 Mar 
      9.